Low-Dose Atropine, the CRL, and the FDA Advisory Committee | Dr. Jennifer Lyerly

The FDA agreed the trial hit its primary endpoint — then rejected the drug anyway. Dr. Jennifer Lyerly fully expected approval explains why the data changed her mind. In October 2025, low-dose atropine's FDA approval felt like a formality to most of optometry. It didn't happen. In this conversation we go through the Phase 3 STAR study — the largest low-dose atropine trial ever run, 847 children, three years — and talk honestly about what it does and doesn't show. DISCLOSURE: No sponsorship, no financial relationship with any manufacturer discussed. Nobody put us up to this. WHERE THINGS STAND (as of publication): FDA issued a Complete Response Letter on October 23, 2025, citing effectiveness rather than safety or product quality. Sydnexis filed a Formal Dispute Resolution Request, and in July 2026 the FDA agreed to convene an advisory committee to review the application. A meeting date has not been announced. The same molecule was approved in the European Union in June 2025. CHAPTERS 0:00 - Where the profession actually stands 0:50 - Why approval felt like a foregone conclusion 1:31 - Reading the headline as "approved" 2:12 - Inside the STAR study: 847 kids, three years 2:40 - A 21% effect, and no dose response 3:28 - What happens when you subset the data 4:22 - The axial length nobody measured 8:39 - The -0.75 D benchmark they were told to hit 10:45 - Why the 13- and 14-year-olds changed everything 11:58 - "I don't want to manipulate the data" 12:37 - The fast-progressor question 14:22 - Who you'd actually prescribe it to - The Myopia Mindset - conversations with the optometrists and myopia specialists actually doing the work. Myopia Mindset Substack: https://myopiamindset.substack.com/ #myopiamanagement #optometry #optometrist #lowdoseatropine #pediatriceyecare